Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials
- PMID: 29115703
- PMCID: PMC5699965
- DOI: 10.1111/ajad.12635
Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials
Abstract
Background and objectives: Moderators of treatment response to serotonin reuptake inhibitor sertraline (SRT) for cocaine dependence were assessed in two randomized, double blind, placebo-controlled clinical trials.
Methods: Generalized estimating equation modeling was performed on data from cocaine-dependent volunteers randomized to receive SRT or placebo (N = 126) who completed >2-week drug-free residential portions of the 12-week trials, in which subsequent outpatient treatment (weeks 3-12) included weekly cognitive behavioral therapy and thrice-weekly supervised urine toxicology.
Primary outcome measure: Relapse (2 consecutive cocaine-positive or missing urines) following residential stay. Potential moderators included treatment, sex, age, race, depression measures, baseline cocaine urine result, and alcohol dependence diagnosis (ADDx).
Results: Odds ratios (OR) for relapse showed placebo-treated participants were significantly more likely to relapse than SRT participants. Regardless of treatment condition, participants more likely to relapse were male, and those with lower Hamilton depression ratings, or baseline cocaine-negative urines. Older subjects or those with current ADDx had higher relapse risk than those without ADDx; however, treating older or ADDx participants with SRT reduced cocaine relapse more than placebo.
Discussion and conclusions: Women or those with more severe cocaine use or depressive symptoms may have fewer cocaine relapses regardless of medication treatment. SRT at 200 mg reduced cocaine relapse more than placebo, especially in older participants or in those with comorbid ADDx.
Scientific significance: SRT may be efficacious to support relapse prevention among cocaine-dependent patients in the context of brief residential followed by outpatient treatment, especially in older participants or those with comorbid alcohol/cocaine dependence. (Am J Addict 2017;26:807-814).
© 2017 American Academy of Addiction Psychiatry.
Conflict of interest statement
Figures
Similar articles
-
Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.Addiction. 2012 Jan;107(1):131-41. doi: 10.1111/j.1360-0443.2011.03552.x. Epub 2011 Oct 10. Addiction. 2012. PMID: 21707811 Free PMC article. Clinical Trial.
-
Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms.J Clin Psychopharmacol. 2014 Apr;34(2):234-9. doi: 10.1097/JCP.0000000000000062. J Clin Psychopharmacol. 2014. PMID: 24525654 Free PMC article. Clinical Trial.
-
Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial.J Clin Psychopharmacol. 2003 Dec;23(6):553-62. doi: 10.1097/01.jcp.0000095346.32154.41. J Clin Psychopharmacol. 2003. PMID: 14624185 Clinical Trial.
-
A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence.Drug Alcohol Depend. 2009 Jan 1;99(1-3):317-21. doi: 10.1016/j.drugalcdep.2008.06.006. Epub 2008 Jul 21. Drug Alcohol Depend. 2009. PMID: 18644685 Free PMC article. Clinical Trial.
-
Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence.Drug Alcohol Depend. 2006 Oct 15;85(1):12-8. doi: 10.1016/j.drugalcdep.2006.03.005. Epub 2006 Apr 18. Drug Alcohol Depend. 2006. PMID: 16621339 Clinical Trial.
Cited by
-
Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: a Bayesian meta-analysis.Eur J Clin Pharmacol. 2022 Jun;78(6):931-942. doi: 10.1007/s00228-022-03303-4. Epub 2022 Mar 5. Eur J Clin Pharmacol. 2022. PMID: 35246699 Review.
-
Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review.Pharmacol Rev. 2022 Jan;74(1):119-140. doi: 10.1124/pharmrev.121.000367. Pharmacol Rev. 2022. PMID: 34987089 Free PMC article. Review.
-
Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial.Drug Alcohol Depend. 2021 Nov 1;228:109054. doi: 10.1016/j.drugalcdep.2021.109054. Epub 2021 Sep 23. Drug Alcohol Depend. 2021. PMID: 34600245 Free PMC article. Clinical Trial.
References
-
- DASIS. Drug and Alcohol Services Information System; Substance Abuse and Mental Health Services Administration CfBHSaQ, editor. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. Treatment Episode Data Set (TEDS) : 2002–2012. BHSIS Series S-71.
-
- DHHS, SAMHSA; Department of Health and Human Services, editor. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2015.
-
- USDHHS. Mental Health: A report from the surgeon general. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, NIH, NIMH; 1999.
-
- Spronk D, van Wel J, Ramaekers J, Verkes R. Characterizing the cognitive effects of cocaine: a comprehensive review. Neurosci Biobehav Rev. 2013;37(8):1838–1859. - PubMed
-
- Perez CM, Suarez E, Torres EA. Epidemiology of hepatitis C infection and its public health implications in Puerto Rico. P R Health Sci J. 2004;23(2 Suppl):11–28. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
